Hong Kong Stock Movement | HENGRUI PHARMA (01276) Rises Nearly 3% as Fumarate Tegileridine Injection Receives Clinical Trial Approval

Stock News11-18

HENGRUI PHARMA (01276) rose nearly 3%, reaching HK$72.35 by the time of writing, with a trading volume of HK$37.59 million.

On November 17, the company announced that its subsidiary, Jiangsu Hengrui Pharmaceuticals Co., Ltd., received approval from the National Medical Products Administration (NMPA) for clinical trials of Fumarate Tegileridine Injection. The trials are set to commence shortly.

Fumarate Tegileridine Injection is a μ-opioid receptor (MOR) biased small-molecule agonist. It was approved for domestic market launch in January 2024, marking China's first independently developed Class 1 opioid analgesic.

A similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, was approved for sale in the U.S. in 2020. Jiangsu Nhwa Pharmaceutical Co., Ltd. secured exclusive licensing rights from Trevena, and Oliceridine was approved in China in May 2023, though no sales data is currently available.

To date, the cumulative R&D investment for Fumarate Tegileridine Injection-related projects amounts to approximately RMB 200 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176246215?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176246215","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Movement | HENGRUI PHARMA (01276) Rises Nearly 3% as Fumarate Tegileridine Injection Receives Clinical Trial Approval","media":"Stock News","content":"<p>HENGRUI PHARMA (01276) rose nearly 3%, reaching HK$72.35 by the time of writing, with a trading volume of HK$37.59 million.</p>\n<p>On November 17, the company announced that its subsidiary, Jiangsu Hengrui Pharmaceuticals Co., Ltd., received approval from the National Medical Products Administration (NMPA) for clinical trials of Fumarate Tegileridine Injection. The trials are set to commence shortly.</p>\n<p>Fumarate Tegileridine Injection is a μ-opioid receptor (MOR) biased small-molecule agonist. It was approved for domestic market launch in January 2024, marking China's first independently developed Class 1 opioid analgesic.</p>\n<p>A similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, was approved for sale in the U.S. in 2020. Jiangsu Nhwa Pharmaceutical Co., Ltd. secured exclusive licensing rights from Trevena, and Oliceridine was approved in China in May 2023, though no sales data is currently available.</p>\n<p>To date, the cumulative R&D investment for Fumarate Tegileridine Injection-related projects amounts to approximately RMB 200 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | HENGRUI PHARMA (01276) Rises Nearly 3% as Fumarate Tegileridine Injection Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | HENGRUI PHARMA (01276) Rises Nearly 3% as Fumarate Tegileridine Injection Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-18 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA (01276) rose nearly 3%, reaching HK$72.35 by the time of writing, with a trading volume of HK$37.59 million.</p>\n<p>On November 17, the company announced that its subsidiary, Jiangsu Hengrui Pharmaceuticals Co., Ltd., received approval from the National Medical Products Administration (NMPA) for clinical trials of Fumarate Tegileridine Injection. The trials are set to commence shortly.</p>\n<p>Fumarate Tegileridine Injection is a μ-opioid receptor (MOR) biased small-molecule agonist. It was approved for domestic market launch in January 2024, marking China's first independently developed Class 1 opioid analgesic.</p>\n<p>A similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, was approved for sale in the U.S. in 2020. Jiangsu Nhwa Pharmaceutical Co., Ltd. secured exclusive licensing rights from Trevena, and Oliceridine was approved in China in May 2023, though no sales data is currently available.</p>\n<p>To date, the cumulative R&D investment for Fumarate Tegileridine Injection-related projects amounts to approximately RMB 200 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2580892862.HKD","symbol_name":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","start_time":0,"source_url":"","article_id":"1176246215","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176246215","pubTimestamp":1763430864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (01276) rose nearly 3%, reaching HK$72.35 by the time of writing, with a trading volume of HK$37.59 million. On November 17, the company announced that its subsidiary, Jiangsu Hengrui...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK0196":"行业龙头","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0239":"医药制造","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","01276":"恒瑞医药","BK0183":"MSCI概念","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359201612.USD":"贝莱德中国基金A2","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0188":"融资融券","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0012":"证金概念","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0028":"国家队","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK1191":"制药","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0060":"抗癌","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"港股动向|恒瑞医药(01276)涨近3%富马酸替吉列定注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"HENGRUI PHARMA (01276) rose nearly 3%, reaching HK$72.35 by the time of writing, with a trading volume of HK$37.59 million.\nOn November 17, the company announced that its subsidiary, Jiangsu Hengrui Pharmaceuticals Co., Ltd., received approval from the National Medical Products Administration (NMPA) for clinical trials of Fumarate Tegileridine Injection. The trials are set to commence shortly.\nFumarate Tegileridine Injection is a μ-opioid receptor (MOR) biased small-molecule agonist. It was approved for domestic market launch in January 2024, marking China's first independently developed Class 1 opioid analgesic.\nA similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, was approved for sale in the U.S. in 2020. Jiangsu Nhwa Pharmaceutical Co., Ltd. secured exclusive licensing rights from Trevena, and Oliceridine was approved in China in May 2023, though no sales data is currently available.\nTo date, the cumulative R&D investment for Fumarate Tegileridine Injection-related projects amounts to approximately RMB 200 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176246215","isCrawlerRequest":true}